Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Journal of Medicinal Chemistry
|
December 8, 2023
Discovery of JN122, a Spiroindoline-Containing Molecule that Inhibits MDM2/p53 Protein-Protein Interaction and Exerts Robust In Vivo Antitumor Efficacy
Jing Cheng, Ziqin Yan, Kailong Jiang, et al.
European Journal of Medicinal Chemistry
|
August 29, 2019
Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins
Deheng Chen, Tian Lu, Ziqin Yan, et al.
British Journal of Pharmacology
|
March 26, 2021
Discovery of a novel, potent and selective small-molecule inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumour efficacy
Chenglong Liu, Feilong Zhou, Ziqin Yan, et al.
European Journal of Medicinal Chemistry
|
April 6, 2024
Synthesis and biological evaluation of 4-imidazolidinone-containing compounds as potent inhibitors of the MDM2/p53 interaction
Zhitong Lin, Chen Liu, Ziqin Yan, et al.
European Journal of Medicinal Chemistry
|
May 5, 2026
Discovery and characterization of YSA64, a RBM39 degrader with in vivo efficacy and potent cellular activity in pediatric Ewing sarcoma A673
Xilin Lyu, Zhiyi Wang, Yanyan Shen, et al.
European Journal of Medicinal Chemistry
|
April 6, 2022
Discovery of a selective and covalent small-molecule inhibitor of BFL-1 protein that induces robust apoptosis in cancer cells
Xuexin Feng, Ziqin Yan, Feilong Zhou, et al.
Chemical Science
|
June 24, 2021
Diversified strategy for the synthesis of DNA-encoded oxindole libraries
Xuan Wang, Jiaxiang Liu, Ziqin Yan, et al.
Journal of Medicinal Chemistry
|
June 24, 2024
Discovery of a Covalent Inhibitor That Overcame Resistance to Venetoclax in AML Cells Overexpressing BFL-1
Jianfeng Lou, Qianqian Zhou, Xilin Lyu, et al.
Oncotarget
|
April 19, 2015
HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status
Wen-Bin Ou, Jiaqing Zhu, Grant Eilers, et al.
Journal of Medicinal Chemistry
|
March 19, 2025
Synthesis of an RBM39 Degrader That Downregulates CEP192 and Induces Disorganized Spindle Structures
Xilin Lyu, Xiancheng Wang, Dongze Lin, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Journal of Medicinal Chemistry
|
December 8, 2023
Discovery of JN122, a Spiroindoline-Containing Molecule that Inhibits MDM2/p53 Protein-Protein Interaction and Exerts Robust In Vivo Antitumor Efficacy
Jing Cheng, Ziqin Yan, Kailong Jiang, et al.
European Journal of Medicinal Chemistry
|
August 29, 2019
Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins
Deheng Chen, Tian Lu, Ziqin Yan, et al.
British Journal of Pharmacology
|
March 26, 2021
Discovery of a novel, potent and selective small-molecule inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumour efficacy
Chenglong Liu, Feilong Zhou, Ziqin Yan, et al.
European Journal of Medicinal Chemistry
|
April 6, 2024
Synthesis and biological evaluation of 4-imidazolidinone-containing compounds as potent inhibitors of the MDM2/p53 interaction
Zhitong Lin, Chen Liu, Ziqin Yan, et al.
European Journal of Medicinal Chemistry
|
May 5, 2026
Discovery and characterization of YSA64, a RBM39 degrader with in vivo efficacy and potent cellular activity in pediatric Ewing sarcoma A673
Xilin Lyu, Zhiyi Wang, Yanyan Shen, et al.
European Journal of Medicinal Chemistry
|
April 6, 2022
Discovery of a selective and covalent small-molecule inhibitor of BFL-1 protein that induces robust apoptosis in cancer cells
Xuexin Feng, Ziqin Yan, Feilong Zhou, et al.
Chemical Science
|
June 24, 2021
Diversified strategy for the synthesis of DNA-encoded oxindole libraries
Xuan Wang, Jiaxiang Liu, Ziqin Yan, et al.
Journal of Medicinal Chemistry
|
June 24, 2024
Discovery of a Covalent Inhibitor That Overcame Resistance to Venetoclax in AML Cells Overexpressing BFL-1
Jianfeng Lou, Qianqian Zhou, Xilin Lyu, et al.
Oncotarget
|
April 19, 2015
HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status
Wen-Bin Ou, Jiaqing Zhu, Grant Eilers, et al.
Journal of Medicinal Chemistry
|
March 19, 2025
Synthesis of an RBM39 Degrader That Downregulates CEP192 and Induces Disorganized Spindle Structures
Xilin Lyu, Xiancheng Wang, Dongze Lin, et al.
Page
of 3